Received: December 25, 2018 Peer-review started: December 25, 2018 First decision: March 5, 2019 Revised: March 11, 2019 Accepted: April 19, 2019 Article in press: April 19, 2019 Published online: May 21, 2019 Processing time: 147 Days and 16.1 Hours
Abstract
Gastric cancer-associated peritoneal carcinomatosis leads to a poor prognosis and low quality of life. The current systemic chemotherapy processes cannot effectively improve survival. Hyperthermic intraperitoneal chemotherapy (HIPEC) has been used as an alternative treatment to control this disease through recurrence prevention, definitive therapeutic modality, and symptom palliation. Although HIPEC has been demonstrated to yield favorable results mainly in some Asian studies, widespread adoption of this treatment is still debatable before larger prospective randomized controlled clinical trials confirm its effectiveness.
Core tip: Peritoneal carcinomatosis associated with gastric cancer leads to poor clinical outcomes and low quality of life. Hyperthermic intraperitoneal chemotherapy can potentially be used for the control of this disease.